
Warsaw-based Zimmer Biomet Holdings Inc. is reporting third-quarter net income of $231 million, down from $249 million during the same period last year.
Despite the dip in profit, the medical device manufacturer said it topped $2 billion in sales for the quarter, marking a 9.7% year-over-year increase.
CEO Ivan Tornos said in a news release that the company’s performance was anchored by 5.6% organic revenue growth in its U.S. business.
“This is highly encouraging, especially as we prepare to launch a second round of new-to-the-world technologies, including the first fully autonomous robot in orthopedics and our iodine treated hip, the world’s first orthopedic implant with Iodine Technology that inhibits bacterial adhesion and prevents biofilm formation to help address Periprosthetic Joint Infections,” Tornos said. “We are excited to launch our iodine treated hip in Japan soon, having received PMDA approval in September.”
Last week, Zimmer Biomet received a Breakthrough Device Designation from the U.S. Food and Drug Administration for its iodine-treated total hip replacement system, which is designed to help address challenges associated with joint replacement procedures for patients at higher risk of infection.
Zimmer Biomet also noted that it completed its $177 million acquisition of Texas-based orthopedic robotics company Monogram Technologies Inc. during the quarter.
The quarterly earnings results were partially offset by what Tornos described as weakness in Latin America, emerging markets in Europe, and non-core businesses.
You can connect to the full earnings report by clicking here.
